Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Printing personalised medicines on demand

Project description

Inkjet printing technology for personalised medication

New technologies and the technological knowledge acquired over the years allow dramatic changes in pharmaceutical production and especially the transformation of drugs into personalised medicines. Inkjet printing technology emerges as a method to realise ‘pharmacy-on-demand’, whose concept is the delivery of exact doses of drugs on porous substrates. The EU-funded PrintMed project will demonstrate the viability of the technology that consists of printing highly accurate amounts of a solution containing levothyroxine onto a porous tablet. The project will combine modelling instruments with pioneering characterisation technologies to improve the understanding of printed drug-containing ink-like solutions in porous dosage unit matrices. The technology will deliver more effective and targeted medication, decrease drug waste, reduce medical costs and pave the way for other personalised medicines.

Objective

"Methods of pharmaceutical manufacturing are likely to change dramatically over the coming years. Driven by the knowledge and technology that is already available in other sectors, the processing of drugs into dosage units can be transformed into a “pharmacy-on-demand” process that allows individual dosing, based on criteria relevant for the effective use of the drug in an individual patient. One approach to achieve “pharmacy-on-demand” is the use of inkjet printing technology to deliver an exact dose of drugs on porous substrates. This proof-of-concept project is based on knowledge we acquired during my ERC AdG project on processes of printing on paper using inkjet printing. We will demonstrate the viability of ""printing"" highly accurate amounts of a solution containing levothyroxine, prescribed for hypothyroidism, onto a porous tablet. Modelling tools will be combined with cutting-edge characterization technologies to push the understanding of printed drug-containing inklike solutions in porous dosage unit matrices. This project will transfer pharmaceutical formulation and product design of individual dosage forms with the use of inkjet printing technique to the pharmaceutical community. They can work on clinical approval tests of the developed oral dosage forms and move these products toward clinical use. The patients will benefit directly from development of this production technique, because a much more effective and targeted medication can be provided. The next step will be the development of the inkjet printing technique for other personalized medicines such as pain killers for children, hormones, biomacromolecules, psychoactive and anticancer drugs. Individually-dosed medicines will allow for substantial decrease of drug waste and thus overall reduction of medical expenses."

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2020-PoC

See all projects funded under this call

Host institution

UNIVERSITY OF STUTTGART
Net EU contribution
€ 150 000,00
Address
KEPLERSTRASSE 7
70174 Stuttgart
Germany
Region
Baden-Württemberg Stuttgart Stuttgart, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)